Sichuan Kelun-Biotech Unveils Positive Results from Multiple Innovative Drug Studies at 2025 ESMO Congress

Reuters

10/20

<a href="https://laohu8.com/S/002422">Sichuan Kelun</a>-Biotech Unveils Positive Results from Multiple Innovative Drug Studies at 2025 ESMO Congress

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the presentation of results from multiple clinical studies at the 2025 European Society for Medical Oncology (ESMO) Congress, held in Berlin, Germany from October 17 to 21, 2025. The studies included data on sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate $(ADC)$, trastuzumab botidotin (A166), a HER2-directed ADC, and SKB315, a Claudin18.2 ADC. Two studies of sac-TMT were selected for Late Breaking Abstract oral presentation, including a Phase 3 study in EGFR-mutated non-small cell lung cancer following progression on EGFR-tyrosine kinase inhibitors. The company also reported ongoing research on SKB315 in combination with immunotherapy and as monotherapy in tumors expressing Claudin18.2. The company cautioned that these drugs are not yet approved for all indications and may not ultimately be successfully developed or commercialized.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2576004457"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576004457\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576004457?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 07:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576004457","market":"fut","top_or_hot":-1,"title":"Sichuan Kelun-Biotech Unveils Positive Results from Multiple Innovative Drug Studies at 2025 ESMO Congress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/002422\">Sichuan Kelun</a>-Biotech Unveils Positive Results from Multiple Innovative Drug Studies at 2025 ESMO Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the presentation of results from multiple clinical studies at the 2025 European Society for Medical Oncology (ESMO) Congress, held in Berlin, Germany from October 17 to 21, 2025. The studies included data on sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, trastuzumab botidotin (A166), a HER2-directed ADC, and SKB315, a Claudin18.2 ADC. Two studies of sac-TMT were selected for Late Breaking Abstract oral presentation, including a Phase 3 study in EGFR-mutated non-small cell lung cancer following progression on EGFR-tyrosine kinase inhibitors. The company also reported ongoing research on SKB315 in combination with immunotherapy and as monotherapy in tumors expressing Claudin18.2. The company cautioned that these drugs are not yet approved for all indications and may not ultimately be successfully developed or commercialized.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sichuan Kelun-Biotech Unveils Positive Results from Multiple Innovative Drug Studies at 2025 ESMO Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSichuan Kelun-Biotech Unveils Positive Results from Multiple Innovative Drug Studies at 2025 ESMO Congress\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-20 07:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/002422\">Sichuan Kelun</a>-Biotech Unveils Positive Results from Multiple Innovative Drug Studies at 2025 ESMO Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the presentation of results from multiple clinical studies at the 2025 European Society for Medical Oncology (ESMO) Congress, held in Berlin, Germany from October 17 to 21, 2025. The studies included data on sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, trastuzumab botidotin (A166), a HER2-directed ADC, and SKB315, a Claudin18.2 ADC. Two studies of sac-TMT were selected for Late Breaking Abstract oral presentation, including a Phase 3 study in EGFR-mutated non-small cell lung cancer following progression on EGFR-tyrosine kinase inhibitors. The company also reported ongoing research on SKB315 in combination with immunotherapy and as monotherapy in tumors expressing Claudin18.2. The company cautioned that these drugs are not yet approved for all indications and may not ultimately be successfully developed or commercialized.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002422","symbol_name":"科倫藥業","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251019:nNDL7FfVX3:1","article_id":"2576004457","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576004457","pubTimestamp":1760916746,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the presentation of results from multiple clinical studies at the 2025 European Society for Medical Oncology  Congress, held in Berlin, Germany from October 17 to 21, 2025. The studies included data on sacituzumab tirumotecan , a TROP2-directed antibody-drug conjugate , trastuzumab botidotin , a HER2-directed ADC, and SKB315, a Claudin18.2 ADC. Two studies of sac-TMT were selected for Late Breaking Abstract oral presentation, including a Phase 3 study in EGFR-mutated non-small cell lung cancer following progression on EGFR-tyrosine kinase inhibitors. The company also reported ongoing research on SKB315 in combination with immunotherapy and as monotherapy in tumors expressing Claudin18.2. The company cautioned that these drugs are not yet approved for all indications and may not ultimately be successfully developed or commercialized.Disclaimer: This news brief was created by Public Technologies  using generative artificial inte","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"002422":"科伦药业","BK1161":"生物科技","06990":"科伦博泰生物-B","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK0060":"抗癌","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","BK0239":"医药制造"},"translate_title":"四川科伦生物在2025年ESMO大会上公布多项创新药物研究积极成果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002422":0.9,"06990":0.9},"content_text":"Sichuan Kelun-Biotech Unveils Positive Results from Multiple Innovative Drug Studies at 2025 ESMO Congress\n    \n\n        Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the presentation of results from multiple clinical studies at the 2025 European Society for Medical Oncology (ESMO) Congress, held in Berlin, Germany from October 17 to 21, 2025. The studies included data on sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate $(ADC)$, trastuzumab botidotin (A166), a HER2-directed ADC, and SKB315, a Claudin18.2 ADC. Two studies of sac-TMT were selected for Late Breaking Abstract oral presentation, including a Phase 3 study in EGFR-mutated non-small cell lung cancer following progression on EGFR-tyrosine kinase inhibitors. The company also reported ongoing research on SKB315 in combination with immunotherapy and as monotherapy in tumors expressing Claudin18.2. The company cautioned that these drugs are not yet approved for all indications and may not ultimately be successfully developed or commercialized.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}